Original article
Technical
Biliary complications of arterial chemoembolization of hepatocellular carcinoma

https://doi.org/10.1016/j.diii.2015.06.017Get rights and content
Under an Elsevier user license
open archive

Abstract

Rationale and background

Transarterial chemoembolization (TACE) is the most frequently used palliative therapy for unresectable hepatocellular carcinoma (HCC). It is a safe and effective procedure with few major and minor complications. Rarely, biliary complications are also encountered following TACE. The goal of our study was to investigate the incidence and the presentation of biliary complications following TACE in patients with HCC.

Material and methods

In this retrospective study, data of patients with HCC who underwent TACE between June 2002 to December 2014 were obtained from the records. Their detailed information about the procedure of TACE, diagnosis of biliary complications and subsequent management details were reviewed.

Result

One hundred and sixty-eight patients with HCC underwent 305 procedures of TACE. Of these, biliary complications of various severities developed in 6 (3.6%) patients leading to an incidence of 1.9% (6/305). Minimal intrahepatic biliary dilatation (IHBD) occurred in three, biliary stricture in one and intrahepatic biloma in two patients. Supportive management was undertaken for IHBD patients while percutaneous aspiration and naso-biliary drainage was performed for the infected bilomas.

Conclusion

Biliary complications following TACE are infrequent. Diagnosis should be suspected clinically and confirmed with imaging. Treatment depends on the severity. Enforcing specific measures can minimize its frequency.

Keywords

Hepatocellular carcinoma (HCC)
Transarterial chemoembolization (TACE)
Biliary complications
Biloma

Abbreviations

TACE
transarterial chemoembolization
HCC
hepatocellular carcinoma
AFP
alpha-fetoprotein
MDCT
multi-detector computed tomography
MRI
magnetic resonance imaging
EASL
European Association for the Study of Liver
BCLC
Barcelona clinic of liver cancer
IHBD
intrahepatic biliary dilatation
mRECIST
modified response evaluation criteria in solid tumors

Cited by (0)